Identification and therapeutic targeting of signaling pathways in Ruxolitinib resistant cells

Ruxolitinib/Jakafi is a current front line therapy for JAK2-mediated myelofibrosis.

AACR Annual Meeting 2015
READ MORE

STAY INFORMED

Top